Related references
Note: Only part of the references are listed.Murine erythropoietic impairment induced by paclitaxel: Interactions of GATA-1 and erythroid Kruppel-like transcription factors, apoptotic related proteins and erythropoietin receptor
Maria Victoria Aguirre et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression
H. Chen et al.
BRITISH JOURNAL OF CANCER (2009)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Paclitaxel Directly Binds to Bcl-2 and Functionally Mimics Activity of Nur77
Cristiano Ferlini et al.
CANCER RESEARCH (2009)
Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle - A new strategy against peritoneal dissemination of gastric cancer
Jun Yamada et al.
CANCER LETTERS (2008)
A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent In vivo therapeutic activity
Alessandra Banzato et al.
CLINICAL CANCER RESEARCH (2008)
Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access (R) OV Monitor assay on the UniCel (R) Dxl 800 Immunoassay System
Stefan Holdenrieder et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2008)
Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: A review of complications and completion rates
Lisa M. Landrum et al.
GYNECOLOGIC ONCOLOGY (2008)
Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions?
Christopher Alan Maxwell et al.
JOURNAL OF CELL SCIENCE (2008)
Design, synthesis and applications of hyaluronic acid-paclitaxel bioconjugates
Francesca Leonelli et al.
MOLECULES (2008)
The promise and perils of 'targeted therapy' of advanced ovarian cancer
Maurie Markman
ONCOLOGY (2008)
Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies
Maurie Markman
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?
Patrick Petignat et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Estimates of the cancer incidence and mortality in Europe in 2006
J. Ferlay et al.
ANNALS OF ONCOLOGY (2007)
Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: From laboratory bench to bedside
Eelco de Bree et al.
CANCER TREATMENT REVIEWS (2006)
Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination
E. de Bree et al.
EJSO (2006)
HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer
Antonio Rosato et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2006)
Normal structure, function, and histology of mucosa-associated lymphoid tissue
Mark F. Cesta
TOXICOLOGIC PATHOLOGY (2006)
CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use
MJ Duffy et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
Models of ovarian cancer - Are we there yet?
K Garson et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2005)
Liposome-based approaches to overcome anticancer drug resistance
C Mamot et al.
DRUG RESISTANCE UPDATES (2003)
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation
H Gelderblom et al.
EUROPEAN JOURNAL OF CANCER (2001)
Hematotoxicity induced by paclitaxel:: In vitro and in vivo assays during normal murine hematopoietic recovery
JA Juaristi et al.
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY (2001)
Adhesion receptors on haematopoietic progenitor cells
JYH Chan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
